News Sentiment

VTGN sentiment intelligence

VistaGen Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 42 Balanced news tone 53 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 0.26 Week of 10 Jul 2026
Weighted tone 42/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

76/100 classification confidence.

Company focus 45

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

+3.7% over one week, -55.2% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Is Vistagen Therapeutics, Inc. (VTGN) Stock Facing New Challenges After PALISADE-4 Clinical Trial Results?

Market Reaction

Balanced read

66/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 76/100 classification
One-week reaction 3.7% Price confirming higher
Trend fit Trend inactive -55.2% over four weeks
Fair value -91.4% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 2
Neutral 35
Negative 16

Relevance

Why the article matched

Direct first
Direct company coverage 45
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 11
Market source 10
TradingView 7
Stocktwits 2
Business Wire 2
simplywall.st 2
Investing.com Nigeria 1
Moomoo 1

Event Lens

What the news is about

Classified themes
Market update 23
Earnings 22
Regulatory and legal 3
Analyst action 2
Balance sheet 2
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-53 of 53